September 19, 2013 – Corindus Vascular Robotics announced the PRECISION Registry, an ongoing clinical study aimed at collecting data on the patterns of use, safety and effectiveness in the delivery and manipulation of percutaneous coronary intervention (PCI) devices. Giora Weisz, associate professor of Medicine at Columbia University Medical Center, will lead the study.
“Although manual PCI procedures are a widely accepted practice, I believe there is an opportunity for improvements to be made in stent size selection and precision movements that can only be offered with robotic assistance,” said Weisz. “We have seen initial clinical indications linked to the benefits of robotics during the CorPath PRECISE clinical trial, published recently, and with the launch of the PRECISION Registry, we expect to see continued trending towards improved clinical output resulting from the routine practice of robotics during PCIs.”
Corindus’ CorPath 200 System is the first and only U.S. Food and Drug Administration (FDA)-cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. During a CorPath angioplasty procedure, the interventional cardiologist sits in the radiation shielded interventional cockpit. Using robotic precision, the interventional cardiologist advances stents and guidewires via a joystick with millimeter-by-millimeter precision. CorPath may improve clinical outcomes by enabling precise measurement of the anatomy, which could potentially lead to better stent placements.
As a result of the increasing interest in the CorPath System, Corindus Vascular Robotics has grown its patent portfolio to now include more than 30 issued patents worldwide. Additionally, following FDA clearance in July 2012, Corindus has increased its workforce, including an expansion of its sales team, and has recently relocated its office to a larger facility in Waltham, Mass.
For more information: www.corindus.com
April 24, 2024 
